Expert Discusses Advances in Treating CLL

Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
 
BY GINA COLUMBUS @ginacolumbusonc
PUBLISHED: JUNE 13, 2017
Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).

At a median follow-up of 44 months for the Imbruvica arm, the progression-free survival (PFS) was significantly longer for Imbruvica compared with Arzerra, at a median PFS not reached versus eight months (three-year PFS 59 percent vs 3 percent), with significant benefit across subgroups. The PFS with Imbruvica for the 11q deletion subgroup reportedly had the most favorable outcome; however, it was not statistically different for patients with 17p deletion or 11q deletion or without these abnormalities.

At the time of analysis, 68 percent of patients randomized to Arzerra crossed over to Imbruvica. The overall survival (OS) rate for Imbruvica at three years was 74 percent. The overall response rate (ORR) with Imbruvica was 91 percent, with complete remission (CR)/CR with incomplete platelet recovery rates (CRi) — now 9 percent — increasing over time.

John C. Byrd, M.D., D. Warren Brown Chair of Leukemia Research, professor of Medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, was the lead author of the long-term findings. In an interview with CURE, Byrd shed light on the game-changing efficacy of Imbruvica in CLL.

Can you discuss the updated findings from the RESONATE study?

The RESONATE study is the first randomized phase III study that reported out the first-in-class irreversible inhibitor Imbruvica. This was a randomized trial that compared Imbruvica in second or greater line to Arzerra, a standard of care for patients with CLL at that time. Patients were randomized to one or the other therapy; at the initial part of the trial, there was not a crossover. After it was clear that Imbruvica had significant activity, loss of equipoise existed for the control, and a crossover was allowed. What was presented at the 2017 ASCO Annual Meeting was long-term follow-up — a median of 45 months for most patients and, for some patients, out as far as 4.5 years. 

The results continue to show the response over time with Imbruvica. The ORR is currently 91 percent. There is a slight increase in complete remissions; most notably, the short-term results of progression-free survival (PFS) and overall survival (OS). The PFS at that median extended follow-up time still has not been reached for all the genetic groups. It appears that the 11q deletion group is doing the best. Although, when you look at all of the genetic groups of patients enrolled on the study, we still see all groups doing well and not statistically different. 

With any new drug that’s given for a long time, we worry about toxicities emerging. What has been quite remarkable with long-term follow-up is that the toxicities being seen are very similar as to what was seen in the phase II study. There is an increased risk of atrial fibrillation with Imbruvica, increased bruising, bleeding, and rash, but those really have not increased over time with the initial report.




Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Examining the Safety of CLL Medication
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Drug Provides High Response Rate in CLL
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.  
Treatment Stages for a Rare Leukemia
THERE ARE THREE STAGES of treatment for acute promyelocytic leukemia: induction therapy, consolidation therapy and maintenance therapy.
Related Videos
William G. Wierda on the Treatment of CLL
CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.
Dr. Stuart Goldberg Answers Common Questions From CML Patients
Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.
x
//For side ad protocol